Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Lessened by Prudential Financial Inc.

Prudential Financial Inc. reduced its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 45.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,495 shares of the specialty pharmaceutical company's stock after selling 9,761 shares during the quarter. Prudential Financial Inc.'s holdings in Jazz Pharmaceuticals were worth $1,398,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in JAZZ. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth $25,000. Jones Financial Companies Lllp raised its position in Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 130 shares during the period. UMB Bank n.a. raised its position in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after purchasing an additional 129 shares during the period. Lindbrook Capital LLC raised its position in Jazz Pharmaceuticals by 82.6% in the fourth quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company's stock valued at $48,000 after purchasing an additional 176 shares during the period. Finally, GAMMA Investing LLC raised its position in Jazz Pharmaceuticals by 49.8% in the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company's stock valued at $76,000 after purchasing an additional 206 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Jazz Pharmaceuticals Price Performance

Shares of JAZZ traded down $8.84 during trading hours on Thursday, hitting $101.28. 393,905 shares of the company were exchanged, compared to its average volume of 986,135. The firm has a fifty day simple moving average of $130.49 and a 200-day simple moving average of $122.78. The company has a market capitalization of $6.15 billion, a PE ratio of 14.26, a PEG ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Insider Activity

In related news, CMO Robert Iannone sold 7,080 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $123.75, for a total value of $185,625.00. Following the sale, the chief executive officer now owns 440,307 shares of the company's stock, valued at approximately $54,487,991.25. This represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,023,305 over the last quarter. Corporate insiders own 4.20% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Piper Sandler reissued an "overweight" rating and issued a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday. UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Finally, Barclays restated an "overweight" rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.